Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sanofi Japan to Sharpen Focus on Priority Pipelines as It Eyes Turnaround after 2022: President
December 1, 2020
- AstraZeneca Japan Exec Vows Thorough Safety Evaluation for COVID-19 Vaccine
December 1, 2020
- Demand for Nesp Biosimilars Spiking as Hospitals Turn to Cheaper Meds in Dialysis Care, Shipment Control Triggered
December 1, 2020
- Abbott Japan Taps Managing Exec Officer Takechi as New President
December 1, 2020
- Keytruda-Chemo Combo Filed for 1st Line Esophageal Cancer in Japan
December 1, 2020
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Jardiance Filed for Chronic Heart Failure in Japan: BI/Lilly
November 30, 2020
- Sales Rep Promotions Up in All Channels in September: Intage
November 30, 2020
- Takeda Seeks Japan Nod for Zejula Tablet Form
November 27, 2020
- COVID-19 Pandemic Could Have Negative Impact of Up to 170 Billion Yen on Japan Drug Market in FY2020: IQVIA
November 27, 2020
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- Vibegron Fails in US PII Trial for IBS Pain: Urovant
November 26, 2020
- Shionogi, Nagasaki Univ., Kitasato Institute Join Forces on Antimalarial Drug Research
November 26, 2020
- Dupixent Auto-Injector Now Available: Sanofi
November 26, 2020
- Nippon Shinyaku Files Uptravi for CTEPH
November 26, 2020
- Takeda to Take Full Control of Nihon Pharm as Plasma Biz Grows
November 25, 2020
- Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake
November 24, 2020
- Takeda Launches Zejula, 2nd PARP Inhibitor in Japan
November 24, 2020
- Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally
November 20, 2020
- Gilead’s JAK Med Hits Shelves in Japan; Launch Being Prepped for Oral Semaglutide, Rakuten Photoimmunotherapy
November 19, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…